Drug Interaction Report
1 potential interaction and/or warning found for the following 2 drugs:
- ravulizumab
- Riabni (rituximab)
Interactions between your drugs
riTUXimab ravulizumab
Applies to: Riabni (rituximab), ravulizumab
Consumer information for this interaction is not currently available.
MONITOR: Theoretically, the complement inhibitors eculizumab, ravulizumab, and zilucopan may reduce the complement-dependent pharmacodynamic effects of rituximab. The proposed mechanism is related to the potential inhibitory effect of complement inhibitors on complement-dependent cytotoxicity of rituximab. However, clinical data evaluating the interaction are not available and the significance of this effect is unknown.
MANAGEMENT: Until more information is available, caution and closer monitoring for decreased efficacy of rituximab is advised if the complement inhibitors eculizumab, ravulizumab, or zilucopan are used concurrently.
Drug and food interactions
No alcohol/food interactions were found with the drugs in your list. However, this does not necessarily mean no food interactions exist. Always consult your healthcare provider.
Therapeutic duplication warnings
No duplication warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
Report options
- Switch to professional interaction data
- Email this report to a friend, doctor, or patient
- Ask questions, find answers
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
See also:
Empaveli
Empaveli (pegcetacoplan) is an immunosuppressant that is given by subcutaneous (under the skin) ...
Enspryng
Enspryng is used to treat neuromyelitis optica spectrum disorder (NMOSD) in adults who are ...
Taltz
Taltz (ixekizumab) is used to treat plaque psoriasis, psoriatic arthritis, and ankylosing ...
Zilbrysq
Zilbrysq (zilucoplan) is a C5 inhibitor used to treat generalized myasthenia gravis (gMG) in AChR ...
Rystiggo
Rystiggo is used to treat generalized myasthenia gravis (gMG) in adults who are acetylcholine ...
Mestinon
Mestinon (pyridostigmine) is used to increase muscle strength in conditions such as myasthenia ...
Vyvgart
Vyvgart is used for myasthenia gravis to improve muscle weakness in adults whose myasthenia gravis ...
Ultomiris
Ultomiris (ravulizumab-cwvz) is used for the treatment of myasthenia gravis, paroxysmal nocturnal ...
Fabhalta
Fabhalta is used to treat paroxysmal nocturnal hemoglobinuria (PNH), primary immunoglobulin A ...
Learn more
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.